Exenatide vs Syn-Coll
Side-by-side comparison of key properties, dosing, and research.
GLP-1 / Weight Loss AgonistsCognitive Enhancement
ExenatideSkin & CosmeticAnti-Aging & Longevity
Syn-Coll- Summary
- Exenatide is a GLP-1 receptor agonist derived from the Gila monster lizard peptide exendin-4, with 53% homology to human GLP-1 and natural resistance to DPP-4 degradation. Available as twice-daily (Byetta) or once-weekly (Bydureon) formulation, it is also being studied for Parkinson's disease neuroprotection.
- Syn-Coll is a palmitoylated tripeptide (Palmitoyl Tripeptide-5) that mimics thrombospondin-1 to activate TGF-beta, the primary growth factor driving collagen synthesis in the dermis. It is one of the most mechanistically direct collagen-stimulating peptides in cosmetic formulations.
- Half-Life
- ~2.4 hours (Byetta/twice-daily); Bydureon BCISE: weekly via microsphere release
- Extended (lipid depot in stratum corneum)
- Admin Route
- SubQ
- Topical
- Research
- —
- —
- Typical Dose
- 5 mcg, titrate to 10 mcg
- 0.005-0.05% in formulation
- Frequency
- Twice daily
- Once or twice daily
- Key Benefits
- Blood glucose control in type 2 diabetes
- Weight loss (average 2–3 kg in clinical trials)
- Once-weekly extended-release formulation available
- Reduces appetite and food intake
- Possible neuroprotective in Parkinson's disease (Phase II trials)
- Reduces systemic inflammation
- May protect pancreatic beta cells
- Cardiovascular neutral or potentially protective
- Directly activates TGF-beta for potent collagen synthesis stimulation
- Increases dermal thickness and firmness
- Reduces depth of wrinkles and fine lines
- Improves skin elasticity
- Clinically validated in collagen induction studies
- Complementary to retinoids or vitamin C
- Side Effects
- Nausea (most common, especially initially)
- Vomiting
- Diarrhea
- Headache
- +4 more
- Generally well-tolerated
- Rare mild irritation at high concentrations
- Possible sensitivity in individuals with inflammatory skin conditions
- Stacks With
- —
- —